Summary of Purpose
Proof-of concept clinical trials have indicated that the sphingosine-1-phosphate receptor modulator fingolimod may be efficacious in attenuating brain inflammation and improving clinical outcomes in patients with AIS as a single therapy beyond 4.5 hours of disease onset, or in combination with alteplase within 4.5 hours of disease onset. So in this study the investigators try to determine whether the addition of...Read More →
The following dates are available for this trial. Trial information last updated on 6 November 2016.
|1 Nov 2016||11 Oct 2016||1 Oct 2018||1 Dec 2018||1 Sep 2016||Unavailable|
|Start Date||First Received||1st Completion||Completion||Verification||Results|
- Min Lou, MD,PhD